METTL3 and cancer: This interaction controls m6A levels and impacttumorigenesis, highlighting the therapeutic potential of modulating STUB1 to manage METTL14 levels in cancer treatments.[132] Moreover, METTL3 upregulation in microglia following brain injury is driven by decreased K48‐linked polyubiquitination, orchestrated by TRIP12.